Rationale for Targeting Galectin-1 in Head and Neck Cancer

Dhanya K. Nambiar, PhD
Published: Wednesday, May 03, 2017



Dhanya K. Nambiar, PhD, Stanford University, explains the rationale behind targeting Galectin-1 (Gal-1) in head and neck cancer.

Tumors of the head and neck are very hypoxic, Nambiar says, and Gal-1 is one of the hypoxia-responsive genes, meaning it gets induced during hypoxia.

Additonally, Nambiar says that T-cell responses in tumors are very much limited when they have higher levels of Gal-1.
 
SELECTED
LANGUAGE


Dhanya K. Nambiar, PhD, Stanford University, explains the rationale behind targeting Galectin-1 (Gal-1) in head and neck cancer.

Tumors of the head and neck are very hypoxic, Nambiar says, and Gal-1 is one of the hypoxia-responsive genes, meaning it gets induced during hypoxia.

Additonally, Nambiar says that T-cell responses in tumors are very much limited when they have higher levels of Gal-1.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: How Can We Optimize Outcomes in Head and Neck Cancers with Immunotherapeutic Strategies?Oct 31, 20191.5
Community Practice Connections™: ASCO Direct™ Highlights – 2019 Official Annual Meeting ReviewAug 30, 20201.5
Publication Bottom Border
Border Publication
x